Killik hails major Glaxo deal with Novartis
22nd Apr 2014 12:27
Killik has maintained a 'buy' recommendation on GlaxoSmithKline (GSK), saying that the company's major three-part transaction with Swiss pharmaceuticals peer Novartis on Tuesday will accelerate growth, provide cost savings and generate increased returns. The first part of the deal will see GSK and
Read moreLondon midday: Pharma deals lift stocks as FTSE 100 nears 6,700
22nd Apr 2014 11:36
- FTSE 100 at highest since April 4th - Astra jumps on Pfizer takeover speculation - GSK announces massive three-part deal with Novartis techMARK 2,741.04 +2.28% FTSE 100 6,691.88 +1.01% FTSE 250 16,103.19 +1.23% Heightened M&A activity in the pharmaceutical sector gave UK markets a boost on Tues
Read moreLondon open: Pharma M&A gives UK stocks a lift
22nd Apr 2014 08:59
- FTSE 100 at highest since April 4th - Astra jumps on Pfizer takeover speculation - GSK announces massive three-part deal with Novartis techMARK 2,729.51 +1.85% FTSE 100 6,683.16 +0.87% FTSE 250 16,031.64 +0.78% Strong gains from heavyweight pharmaceutical groups gave UK markets a boost on Tuesd
Read moreGlaxo announces massive three-part deal with Swiss peer Novartis - UPDATE
22nd Apr 2014 07:04
- GSK to return 4bn pounds to shareholders after Novartis three-part deal - Companies to create new consumer business - Novartis to sell Vaccines business to GSK - GSK to sell Oncology portfolio to Novartis - Means 10bn dollar surplus payment to GSK GlaxoSmithKline (GSK) has announced a major three
Read moreBroker tips: Imperial Tobacco, Legal & General, GlaxoSmithKline...
17th Apr 2014 13:13
Goldman Sachs has removed Imperial Tobacco from its 'Conviction List', saying it sees less potential upside from current levels. Nevertheless, the bank kept its 'buy' recommendation and 2,780p target price. Since being added to the Conviction List at the end of January, the stock has gained nearly
Read moreGSK guidance looking 'increasingly challenging', says UBS
17th Apr 2014 11:50
UBS has reduced its target price for GlaxoSmithKline (GSK) from 1,650p to 1,500p, saying that forecasts for earnings growth may continue to prove elusive for the pharmaceutical group. "The prospect of earnings per share (EPS) growth has been delayed year after year at GSK. Consensus - as every year
Read moreTuesday tips round-up: RWS Holdings, GlaxoSmithKline
15th Apr 2014 07:22
As Chinese companies increasingly look to rigorously protect their intellectual property claims in the western world companies such as RWS Holdings will benefit. The firm obtains 70 per cent of its sales from translation services for corporates that allow them to protect their copyrights across a ra
Read moreGSK rocked by bribery claims in Poland
14th Apr 2014 13:37
GlaxoSmithKline (GSK) is facing a criminal investigation in Poland over claims it bribed doctors to promote its lung drug Seretide. 13 people have been charged in connection with the probe launched by Polish prosecutors, according to Poland's Central Anti-Corruption Bureau (CBA) on Monday. The dr
Read moreGSK investigating bribery claims in Iraq
7th Apr 2014 07:25
GlaxoSmithKline (GSK) said it is investigating claims of bribery in its Iraq business. The drugmaker has been accused of hiring government-employed physicians and pharmacists in Iraq as paid sales representatives to improperly increase use of its products. We are investigating allegations of imp
Read moreThursday broker round-up UPDATE
3rd Apr 2014 09:05
Associated British Foods: Citi increases target price from 2350p to 3000p, while its neutral rating remains unchanged. Booker Group: Investec shifts target price from 172p to 178p retaining a buy recommendation. BSkyB: HSBC Holdings moves target price from 600p to 610p, while keeping its underweig
Read moreLondon close: Markets may be underestimating deflation risks in euro area
2nd Apr 2014 17:15
- Stocks extend three-week high - ECB, US data ahead - Antofagasta unharmed by Chile quake techMARK 2,782.92 -0.04% FTSE 100 6,659.04 +0.10% FTSE 250 16,415.96 +0.05% The Footsie ended the day slightly in the blue after the release of largely in-line data on US manufacturing orders alongside a sli
Read moreFusion IP flies as new directors dip in
2nd Apr 2014 15:30
Shares in university intellectual property commercialisation group Frontier IP flew higher on Wednesday after new directors dipped in to buy shares. New James Fish, Finance Director, bought £28,000 worth of shares at 28p per share, while Non-Executive Director Michael Bourne pocketed £49,000 of sha
Read moreBroker tips: Glaxo, Centrica, FirstGroup, ASOS
2nd Apr 2014 12:17
Panmure Gordon has said that the disappointing outcome of GlaxoSmithKline's (GSK) clinical trial for its therapeutic cancer vaccine MAGE-A3 is already priced into the stock. Panmure said that MAGE-A3 could have been one of the "three particularly transformative pipeline opportunities". However, giv
Read moreLondon midday: Markets edge higher but gains limited
2nd Apr 2014 11:48
- Stocks extend three-week high - ECB, US data ahead - Antofagasta unharmed by Chile quake - Sports Direct extends gains on expansion potential techMARK 2,795.73 +0.42% FTSE 100 6,666.62 +0.21% FTSE 250 16,470.77 +0.39% The FTSE 100 had pushed into positive territory by Wednesday lunchtime, but ga
Read moreGlaxo clinical trial disappointment in the price, says Panmure
2nd Apr 2014 10:03
Panmure Gordon has said that the disappointing outcome of GlaxoSmithKline's (GSK) clinical trial for its therapeutic cancer vaccine MAGE-A3 is already priced into the stock. The broker kept its 'hold' recommendation and 1,750p target price. The MAGRIT trial, a phase three trial of its MAGE-A3 anti
Read more